Opus Genetics Inc (NASDAQ: IRD) kicked off on Monday, up 7.45% from the previous trading day, before settling in for the closing price of $1.88. Over the past 52 weeks, IRD has traded in a range of $0.65-$1.92.
Annual sales at Healthcare sector company grew by 24.32% over the past five years. While this was happening, its average annual earnings per share was recorded 73.49%. With a float of $22.61 million, this company’s outstanding shares have now reached $59.91 million.
Opus Genetics Inc (IRD) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Opus Genetics Inc is 62.26%, while institutional ownership is 23.10%. The most recent insider transaction that took place on Dec 26 ’24, was worth 97,600. In this transaction Chief Executive Officer of this company bought 100,000 shares at a rate of $0.98, taking the stock ownership to the 599,150 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President bought 10,000 for $0.98, making the entire transaction worth $9,834. This insider now owns 342,800 shares in total.
Opus Genetics Inc (IRD) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.29 earnings per share (EPS), lower than consensus estimate (set at -0.23) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.13% during the next five years compared to 24.32% growth over the previous five years of trading.
Opus Genetics Inc (NASDAQ: IRD) Trading Performance Indicators
Take a look at Opus Genetics Inc’s (IRD) current performance indicators. Last quarter, stock had a quick ratio of 1.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Opus Genetics Inc (IRD)
Opus Genetics Inc (NASDAQ: IRD) saw its 5-day average volume 0.47 million, a negative change from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 86.15%.
During the past 100 days, Opus Genetics Inc’s (IRD) raw stochastic average was set at 92.85%, which indicates a significant increase from 88.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1600 in the past 14 days, which was higher than the 0.0900 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3400, while its 200-day Moving Average is $1.1100. Nevertheless, the first resistance level for the watch stands at $2.1300 in the near term. At $2.2400, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.3800. If the price goes on to break the first support level at $1.8800, it is likely to go to the next support level at $1.7500. The third support level lies at $1.6400 if the price breaches the second support level.
Opus Genetics Inc (NASDAQ: IRD) Key Stats
The company with the Market Capitalisation of 121.02 million has total of 59,908K Shares Outstanding. Its annual sales at the moment are 10,990 K in contrast with the sum of -57,530 K annual income. Company’s last quarter sales were recorded 2,880 K and last quarter income was -7,420 K.
